Tetrathiomolybdate

Drug Profile

Tetrathiomolybdate

Alternative Names: ATN-224 analogue; Coprexa; TTM

Latest Information Update: 17 Feb 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Michigan
  • Developer Synthetic Biologics
  • Class Heavy metals; Small molecules
  • Mechanism of Action Amyloid beta-protein precursor inhibitors; Chelating agents; Fibroblast growth factor inhibitors; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary fibrosis

Highest Development Phases

  • Suspended Alzheimer's disease; Hepatolenticular degeneration; Huntington's disease; Primary biliary cirrhosis; Pulmonary fibrosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Feb 2012 Adeona Pharmaceuticals is now called Synthetic Biologics
  • 02 Sep 2009 Adeona Pharmaceuticals is seeking partners for further development of Tetrathiomolybdate (http://www.adeonapharma.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top